Published Papers
Nature; November 23, 2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)
Press Releases
December 21, 2009
Agios Pharmaceuticals Awarded Funding From Accelerate Brain Cancer Cure (ABC2) to Support Research into Novel Therapeutics and Diagnostics for Brain Cancer
November 23, 2009
Agios Publishes Groundbreaking Research in Nature Uncovering the New Role of IDH1 Gene Mutation in Brain Cancer
June 29, 2009
FierceBiotech Names Agios Pharmaceuticals as One of the “Fierce 15" Biotech Companies of 2009
May 28, 2009
Agios Pharmaceuticals’ Focus of Drug Research – Cancer Metabolism – Selected for Stand Up To Cancer Grant
May 27, 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO
April 30, 2009
Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR
February 6, 2009
Agios Pharmaceuticals Appoints Charles Sawyers, M.D.,
to Scientific Advisory Board
November 24, 2008
Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts
to Advisory Team
November 24, 2008
Agios Pharmaceuticals Expands Into 21,000 SqFt Facility
July 7, 2008
Agios Pharmaceuticals Closes $33 Million Series A Funding
|
